Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT01815489 |
Other study ID # |
CHS-001 |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
July 2011 |
Est. completion date |
May 2014 |
Study information
Verified date |
May 2014 |
Source |
Wake Forest University Health Sciences |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Necrotizing pancreatitis is a severe form of inflammation of the pancreas with subsequent
destruction of the pancreas (necrosis). Often, this condition manifests in patients as an
overwhelming systemic inflammatory response and multisystem organ failure. Many times the
pancreas can become superinfected with bacteria and other organisms as a result of this
process. Clinicians may decide to sample fluid from the pancreas or pancreatic tissue to
determine the presence of infection. This can be done through surgery with a concurrent
debridement and drainage of the pancreas or by a radiologist using an ultrasound or CT guided
method to sample the pancreatic fluid. These samples are then sent for culture in the
microbiology laboratory. Culture results often reveal 1-2 types of infecting bacteria that
originate from the gastrointestinal tract. The investigators hypothesize that in actuality,
many different kinds of bacteria may infect the pancreas. This project uses molecular DNA
techniques to help identify bacteria present in the pancreas of patients with severe
necrotizing pancreatitis.
Description:
In this study, patients with severe necrotizing pancreatitis will be followed prospectively
throughout their hospital course (anticipated duration of hospitalization ranging between 4-8
weeks). If patients are suspected to have infection of pancreatic necrosis, they will be
consented for enrollment. Patients will be determined by their attending physician to require
either operative intervention or radiologic guided drainage of pancreatic necrosis and
infected peripancreatic fluid. At the time of drainage procedure or intervention, one sample
of peripancreatic fluid will be sent to the hospital's microbiology department for standard
gram stain and bacterial culture identification and a second sample will be frozen for
bacterial DNA analysis. Patients will be followed for the duration of their hospitalization
for in hospital outcomes, mortality and final microbiology culture results. Samples will then
be processed at six months and one year following sample collection for bacterial DNA deep
sequencing analysis and will be compared to bacteria identified using standard culture
technique.